Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

CGT Union Protests Sanofi - Lisieux

A photo shows flags of the CGT union at the entrance of the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

CGT Union Protests Sanofi - Lisieux

A photo shows flags of the CGT union at the entrance of the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

CGT Union Protests Sanofi - Lisieux

A photo shows flags of the CGT union at the entrance of the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM